Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL360950 | 1.00 | PPM1D (0.36) | PPM1DTSHR | |
| SCHEMBL1896226 | 0.96 | PPM1D (0.35) | PPM1DTSHR | |
| SCHEMBL6399612 | 0.96 | TSHR (0.40) | PPM1DTSHR | |
| SCHEMBL29789152 | 0.89 | PPM1D (0.38) | PPM1D | |
| SCHEMBL9985676 | 0.89 | PPM1D (0.38) | PPM1D | |
| SCHEMBL5711230 | 0.89 | PPM1D (0.38) | PPM1D | |
| SCHEMBL5711228 | 0.89 | PPM1D (0.38) | PPM1D | |
| SCHEMBL660447 | 0.89 | PPM1D (0.38) | PPM1D | |
| SCHEMBL277967 | 0.88 | PPM1D (0.33) | PPM1D | |
| SCHEMBL278515 | 0.88 | PPM1D (0.33) | PPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11672791-B2 | Tyrosine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20180008589-A1 | TYROSINE KINASE INHIBITORS | MIDCAP FINANCIAL TRUST | 2018-01-11 | — | — | US | disclosed |
| EP-2125745-B1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES | SANOFI SA (FR) | 2017-02-22 | — | — | EP | disclosed |
| EP-2125745-B1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES | SANOFI SA (FR) | 2017-02-22 | — | — | EP | disclosed |
| US-8742116-B2 | Cycloalkylamine substituted isoquinolone derivatives | SANOFI (FR) | 2014-06-03 | — | — | US | disclosed |
| US-8742116-B2 | Cycloalkylamine substituted isoquinolone derivatives | SANOFI (FR) | 2014-06-03 | — | — | US | disclosed |
| US-8742116-B2 | Cycloalkylamine substituted isoquinolone derivatives | SANOFI (FR) | 2014-06-03 | — | — | US | disclosed |
| US-20100056518-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-03-04 | — | — | US | disclosed |
| US-20100056518-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180008589-A1 | TYROSINE KINASE INHIBITORS | TYRO3, AXL, RET | PPM1D 895/4885TSHR 295/4885 |
| US-11672791-B2 | Tyrosine kinase inhibitors | TYRO3, AXL, RET | PPM1D 895/4885TSHR 295/4885 |
| US-20100056518-A1 | CYCLOALKYLAMINE SUBSTITUTED ISOQUINOLONE DERIVATIVES | MYLK, MYLK2, MYLK3 | PPM1D 316/4885TSHR 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.